JP3253982B2 - Acne cosmetics - Google Patents
Acne cosmeticsInfo
- Publication number
- JP3253982B2 JP3253982B2 JP12878691A JP12878691A JP3253982B2 JP 3253982 B2 JP3253982 B2 JP 3253982B2 JP 12878691 A JP12878691 A JP 12878691A JP 12878691 A JP12878691 A JP 12878691A JP 3253982 B2 JP3253982 B2 JP 3253982B2
- Authority
- JP
- Japan
- Prior art keywords
- acne
- oligosaccharide
- chitin
- chitosan
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、にきび用の化粧料に関
する。TECHNICAL FIELD The present invention relates to a cosmetic for acne .
【0002】[0002]
【従来の技術】従来、にきびの治療剤としては、サリチ
ル酸やレゾルシンが殺菌や角質剥離の作用を有する有効
成分として化粧料に配合されている。また、医薬品とし
ては、上記サリチル酸の他、ステロイド等が皮膚外用剤
に配合されたものがある。2. Description of the Related Art Conventionally, salicylic acid or resorcin has been incorporated into cosmetics as an active ingredient having a disinfecting and exfoliating action as a therapeutic agent for acne. In addition, as pharmaceuticals, there are those in which steroids and the like are added to the external preparation for skin in addition to salicylic acid.
【0003】[0003]
【発明が解決しようとする課題】しかしながら、上記サ
リチル酸やレゾルシンは皮膚に対する刺激等、安全性の
面で問題があり、またステロイド製剤は副作用の面で問
題がある。However, the above-mentioned salicylic acid and resorcinol have problems in safety, such as irritation to the skin, and steroid preparations have a problem in side effects.
【0004】本発明は、このような点に鑑みてなされた
もので、人体に影響が少なく、極めて安全性の高いにき
び用治療剤を提供することを課題とする。[0004] The present invention has been made in view of the above points, and it is an object of the present invention to provide a remedy for acne which has little effect on the human body and is extremely safe.
【0005】[0005]
【課題を解決するための手段】本発明者等は、このよう
な課題を解決するために、安全性の高い天然有機化合物
について鋭意研究を行った結果、キチン,キトサン若し
くはそのオリゴ糖や部分分解物等に、にきび菌に対する
優れた抗菌作用があることを見出し、本発明を完成する
に至った。すなわち、上記課題を解決するための手段
は、プロピオニバクテリウム アクネス(Propionibact
erium acnes )に対して抗菌作用を有するキチンオリゴ
糖、キチン若しくはその部分分解物、又はキトサンオリ
ゴ糖、キトサン若しくはその部分分解物を有効成分とし
て化粧料に配合したことにある。Means for Solving the Problems In order to solve such problems, the present inventors have conducted intensive studies on highly safe natural organic compounds. As a result, chitin, chitosan or its oligosaccharides and partial degradation The present inventors have found that a product or the like has an excellent antibacterial action against acne bacteria, and have completed the present invention. That is, a means for solving the above-mentioned problem is Propionibacterium acnes (Propionibact
In other words , a chitin oligosaccharide having an antibacterial action against erium acnes) , chitin or a partially decomposed product thereof, or a chitosan oligosaccharide, chitosan or a partially decomposed product thereof is incorporated into a cosmetic as an active ingredient.
【0006】[0006]
【実施例】以下、本発明の実施例について説明する。実施例1 本実施例のにきび用治療剤は、キチンオリゴ糖からなる
ものである。本実施例に用いるキチンオリゴ糖は、キト
サンオリゴ糖をN−アセチル化して製造した。本実施例
に用いたキチンオリゴ糖のより具体的な組成は、次表1
のとおりである。Embodiments of the present invention will be described below. Example 1 The therapeutic agent for acne of this example is composed of chitin oligosaccharide. The chitin oligosaccharide used in this example was produced by N-acetylation of chitosan oligosaccharide. The more specific composition of the chitin oligosaccharide used in this example is shown in Table 1 below.
It is as follows.
【表1】 [Table 1]
【0007】次に、このキチンオリゴ糖を、にきび治療
用の薬用成分として化粧料の一例としてのバニシングク
リームに配合した処方例について、その組成を次表2に
示す。Next, the composition of the chitin oligosaccharide formulated in a vanishing cream as an example of a cosmetic as a medicinal component for acne treatment is shown in Table 2 below.
【表2】 [Table 2]
【0008】実施例2 本実施例のにきび用治療剤は、キトサンオリゴ糖からな
るものである。本実施例に用いたキトサンオリゴ糖のよ
り具体的な組成は、次表3のとおりである。 Example 2 The therapeutic agent for acne of this example is composed of chitosan oligosaccharide. The more specific composition of the chitosan oligosaccharide used in this example is as shown in Table 3 below.
【表3】 尚、このキトサンオリゴ糖は、上記実施例1と同様にに
きび治療用の薬用成分として化粧料に配合して使用され
る。[Table 3] In addition, this chitosan oligosaccharide is used as a medicinal component for acne treatment in a cosmetic as in Example 1 above.
【0009】試験例 次に、上記実施例1のキチンオリゴ糖と、実施例2のキ
トサンオリゴ糖とについて、にきび菌であるプロピオニ
バクテリウム アクネス(Propionibacteriumacnes )
に対するMIC(最小生育阻止濃度)を測定した。 Test Example Next, the chitin oligosaccharide of Example 1 and the chitosan oligosaccharide of Example 2 were used for propioni , an acne bacterium.
Bacterium acnes (Propionibacteriumacnes)
MIC (minimum growth inhibitory concentration) was measured.
【0010】(1) 培地 供試菌株として、上記プロピオニバクテリウム アクネ
ス(Propionibacterium acnes )を用い、供試菌株用の
培地としては、次表4のものを用いた。(1) Medium The above-mentioned Propionibacterium acne was used as a test strain.
(Propionibacterium acnes), and the medium for the test strain used was the one shown in Table 4 below.
【表4】 尚、この培地はpH7.0 に調整し、表4の各成分を含有
させて水で総容量1000mlとした。[Table 4] The medium was adjusted to pH 7.0, and contained the components shown in Table 4 to make a total volume of 1,000 ml with water.
【0011】(2)測定方法 上記培地を調整し、16mmφ試験管に分注し、オート
クレーブした。キチンオリゴ糖、キトサンオリゴ糖は、
10%水溶液とし、特にキトサンオリゴ糖はpHを6付
近に調整した後、濾過滅菌を行い、オートクレーブした
各液体培地に加え、10mlとした。そこに、予め種培
養した培養液を0.05ml接種し、適温(細菌37
℃、真菌25℃)で培養を行い、MICを求めた。MI
Cの判定は、96時間後に指示薬BTBを加えてpHの
変化(色の変化)により菌の増殖の有無を判定すること
により行った。(2) Measurement method The above medium was prepared, dispensed into a 16 mmφ test tube, and autoclaved. Chitin oligosaccharide, chitosan oligosaccharide,
A 10% aqueous solution was prepared. In particular, chitosan oligosaccharide was adjusted to pH around 6, then sterilized by filtration, and added to each autoclaved liquid medium to make 10 ml. Then, 0.05 ml of a culture solution which had been seed-cultured in advance was inoculated thereto, and was inoculated at an appropriate temperature (for bacteria 37).
C. and a fungus at 25.degree. C.) to determine the MIC. MI
C was determined 96 hours later by adding the indicator BTB and determining the presence or absence of bacterial growth by a change in pH (change in color).
【0012】(3) 測定結果 MICの値は、キチンオリゴ糖では0.1%、キトサン
オリゴ糖では0.005%であった。この結果からも明
らかなように、実施例1のキチンオリゴ糖と実施例2の
キトサンオリゴ糖は、ともにプロピオニバクテリウム
アクネス(Propionibacterium acnes )に対して抗菌作
用が認められた。(3) Measurement Results The MIC value was 0.1% for chitin oligosaccharide and 0.005% for chitosan oligosaccharide. As is clear from these results, both the chitin oligosaccharide of Example 1 and the chitosan oligosaccharide of Example 2 were propionibacteria.
Antibacterial activity against acnes (Propionibacterium acnes) was observed.
【0013】その他の実施例 尚、上記実施例では、キチンオリゴ糖,キトサンオリゴ
糖のみでにきび用治療剤が構成されていたが、他の成分
を基剤として、その基剤中に配合されてにきび用治療剤
が構成されていてもよい。要は、キチンオリゴ糖,キト
サンオリゴ糖が有効成分として含有されていればよいの
である。尚、本発明において「有効成分として含有され
る」とは、他の基剤中に配合されている場合の他、上記
実施例のようにキチンオリゴ糖,キトサンオリゴ糖のみ
でにきび用治療剤が構成されている場合も含む広い概念
である。[0013] Other embodiments In the above embodiment, chitin oligosaccharides, but acne therapeutic agent only with chitosan oligosaccharide was configured, the other ingredients as a base, are formulated in the base A therapeutic agent for acne may be constituted. The point is that chitin oligosaccharide and chitosan oligosaccharide only need to be contained as active ingredients. In the present invention, the term "contained as an active ingredient" refers to a case where the therapeutic agent for acne is composed of chitin oligosaccharide or chitosan oligosaccharide alone, as described in the above Examples, in addition to the case where it is incorporated in another base. This is a broad concept including the case where it is configured.
【0014】また、該実施例ではキチンオリゴ糖やキト
サンオリゴ糖をにきび用治療剤の有効成分としたが、こ
れらのオリゴ糖に代えて高分子のキチンやキトサン、或
いはその部分分解物を有効成分とすることも可能であ
る。要は、キチンオリゴ糖、キチン若しくはその部分分
解物、又はキトサンオリゴ糖、キトサン若しくはその部
分分解物をにきび用治療剤の有効成分として含有してい
ればよいのである。ただし、高分子のキチンやキトサン
に比べると、上記実施例のようなオリゴ糖は水に可溶で
あり、他の基剤中への配合が容易になる等、にきび用治
療剤として広範囲に使用できるという利点がある。In this embodiment, chitin oligosaccharide or chitosan oligosaccharide was used as an active ingredient of a therapeutic agent for acne. Instead of these oligosaccharides, high molecular weight chitin, chitosan, or a partially decomposed product thereof was used as an active ingredient. It is also possible. The point is that chitin oligosaccharide, chitin or a partial degradation product thereof, or chitosan oligosaccharide, chitosan or a partial degradation product thereof may be contained as an active ingredient of a therapeutic agent for acne. However, compared to high molecular weight chitin and chitosan, the oligosaccharides as in the above examples are soluble in water, and are widely used as a therapeutic agent for acne, as they can be easily incorporated into other bases. There is an advantage that you can.
【0015】さらに、上記実施例では、にきび用治療剤
を化粧料の一例のバニシングクリームに配合する場合に
ついて説明したが、にきび用治療剤の用途はこれに限ら
ず、バニシングクリーム以外の化粧料に使用することも
可能である。 Further, in the above embodiment, the case where the therapeutic agent for acne is blended into a vanishing cream as an example of a cosmetic is described. However, the use of the therapeutic agent for acne is not limited to this. It is also possible to use .
【0016】[0016]
【発明の効果】叙上のように、本発明は、天然多糖類で
あるキチンオリゴ糖やキトサンオリゴ糖、或いはキチン
やキトサン若しくはその部分分解物を有効成分として含
有したものであるため、従来の化粧料や医薬品等に配合
されているサリチル酸,レゾルシン,ステロイド等のよ
うに人体に対する影響もなく、その安全性が高いという
効果がある。また、にきび菌に対する抗菌作用も優れて
いる。As described above, the present invention contains chitin oligosaccharide or chitosan oligosaccharide, which is a natural polysaccharide, or chitin, chitosan or a partially decomposed product thereof as an active ingredient. Unlike salicylic acid, resorcinol, steroids and the like, which are blended in cosmetics and pharmaceuticals, there is no effect on the human body and there is an effect that the safety is high. It also has an excellent antibacterial effect on acne bacteria.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI C08B 37/08 C08B 37/08 A (58)調査した分野(Int.Cl.7,DB名) A61K 7/00 - 7/50 C07H 5/04 - 5/06 C08B 37/08 A61K 31/7016 - 31/702 722 BIOSIS(DIALOG) CA(STN) MEDLINE(STN) WPI(DIALOG)──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. 7 identification code FI C08B 37/08 C08B 37/08 A (58) Field surveyed (Int.Cl. 7 , DB name) A61K 7/00-7 / 50 C07H 5/04-5/06 C08B 37/08 A61K 31/7016-31/702 722 BIOSIS (DIALOG) CA (STN) MEDLINE (STN) WPI (DIALOG)
Claims (1)
opionibacteriumacnes )に対して抗菌作用を有するキ
チンオリゴ糖、キチン若しくはその部分分解物、又はキ
トサンオリゴ糖、キトサン若しくはその部分分解物を有
効成分として配合してなることを特徴とするにきび用化
粧料。(1) Propionibacterium acnes ( Pr
1. A cosmetic composition for acne, comprising chitin oligosaccharide, chitin or a partially degraded product thereof, or chitosan oligosaccharide, chitosan or a partially degraded product thereof, having an antibacterial action against opionibacterium acnes ) as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP12878691A JP3253982B2 (en) | 1991-03-13 | 1991-03-13 | Acne cosmetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP12878691A JP3253982B2 (en) | 1991-03-13 | 1991-03-13 | Acne cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04288017A JPH04288017A (en) | 1992-10-13 |
JP3253982B2 true JP3253982B2 (en) | 2002-02-04 |
Family
ID=14993422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP12878691A Expired - Lifetime JP3253982B2 (en) | 1991-03-13 | 1991-03-13 | Acne cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3253982B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101838404B1 (en) * | 2016-11-15 | 2018-03-13 | 부경대학교 산학협력단 | Composition for preventing or treating Acne containing oligo-chitosan as an effective component |
KR20220120168A (en) * | 2021-02-23 | 2022-08-30 | 주식회사 가인화장품 | Anti-bacterial composition and cosmetic composition for improving of dandruff or acne comprising the same |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19719856A1 (en) * | 1997-05-12 | 1998-11-19 | Henkel Kgaa | Skin care products |
FR2803749B1 (en) * | 2000-01-18 | 2006-09-22 | Pharmascience Lab | USE OF AT LEAST ONE FATTY ESTER FOR THE PREPARATION OF A COMPOSITION INTENDED TO INHIBIT THE ACTIVITY OF ALPHA-REDUCTASE, IN PHARMACY IN PARTICULAR DERMATOLOGY, COSMETICS AND AS A FOOD ADDITIVE |
JP4669595B2 (en) * | 2000-03-23 | 2011-04-13 | ピアス株式会社 | External agent for preventing and treating acne vulgaris and cosmetics containing the external agent |
EP1440683A1 (en) * | 2003-01-23 | 2004-07-28 | Cognis France S.A. | Use of oligoglucosamines in cosmetic or dermatologic compositions |
US20050053664A1 (en) | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
WO2005079314A2 (en) * | 2004-02-13 | 2005-09-01 | Pro-Pharmaceuticals, Inc. | Compositions and methods used to treat acne and candida |
JP4781188B2 (en) * | 2006-07-27 | 2011-09-28 | 株式会社マンダム | Antiseptic disinfectant and cosmetics, pharmaceuticals and foods containing the antiseptic disinfectant |
CN102365075A (en) * | 2009-03-25 | 2012-02-29 | 苏鲁·苏布拉马尼·瓦南加穆迪 | Medical antibacterial cream and preparation method thereof |
CN107536780A (en) * | 2017-10-30 | 2018-01-05 | 广州润虹医药科技股份有限公司 | A kind of removing acne and eliminating mark shin moisturizer and preparation method thereof |
-
1991
- 1991-03-13 JP JP12878691A patent/JP3253982B2/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101838404B1 (en) * | 2016-11-15 | 2018-03-13 | 부경대학교 산학협력단 | Composition for preventing or treating Acne containing oligo-chitosan as an effective component |
KR20220120168A (en) * | 2021-02-23 | 2022-08-30 | 주식회사 가인화장품 | Anti-bacterial composition and cosmetic composition for improving of dandruff or acne comprising the same |
KR102591508B1 (en) | 2021-02-23 | 2023-10-19 | 주식회사 가인화장품 | Anti-bacterial composition and cosmetic composition for improving of dandruff or acne comprising the same |
Also Published As
Publication number | Publication date |
---|---|
JPH04288017A (en) | 1992-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2155222B1 (en) | Extract of trigonella foenum-graecum | |
CN103356738B (en) | Skin disinfection gel and its application | |
EP2937101A1 (en) | Semi-fluidic composition for lubricating, moisture retaining, disinfecting, sterilizing and method using the same | |
EP0185490A2 (en) | Antibacterial cream | |
JP3253982B2 (en) | Acne cosmetics | |
WO2008005194A2 (en) | Method for the eradication of pathogens comprising generating molecular iodine in situ | |
CN105148253A (en) | Antibacterial composition for skin and mucous membrane | |
JPH02501739A (en) | steroid lotion | |
CN105055304A (en) | Leave-on skin care and disinfection gel containing composite sterilization component, and preparation method thereof | |
MX2011009935A (en) | A medicinal cream for diaper rash and a process to make it. | |
KR101642537B1 (en) | A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it | |
MX2011009934A (en) | A medicinal antibacterial cream and a process to make it. | |
WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
Aliagaoglu et al. | Iododerma following topical povidone-iodine application | |
JP3242997B2 (en) | Hyaluronidase activity inhibitor | |
WO2018140707A1 (en) | Synergistic combination of thermolysin and an antibacterial agent to reduce eliminate bacterial biofilms from surfaces | |
NO328979B1 (en) | Use of dichlorobenzyl alcohol for the preparation of a composition for topical treatment of inflammation | |
CN115721706A (en) | Composition for treating eczema dermatitis and preparation method and application thereof | |
JPH09227387A (en) | Drug externally using for treatment of atopic dermatitis | |
JPH0881348A (en) | External preparation for skin | |
WO2021227214A1 (en) | Sterilization and disinfection composition | |
CN113712848A (en) | A foamable oral care composition free of surfactants | |
JPH0517325A (en) | Medicine for dental caries | |
CN111870558A (en) | Composition for inhibiting hyaluronidase activity and skin care product | |
CN111000871A (en) | Oral cavity spray and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071122 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081122 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091122 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091122 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101122 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111122 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111122 Year of fee payment: 10 |